Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports
Saturday, November 14, 2026
  • Login
  • Home
  • World
    • Africa
    • Americas
    • Asia
    • Europe
    • Middle East
    • Oceania
  • Politics
  • Business
  • Technology
  • Health
  • Science
  • Sports
  • Entertainment
  • Culture
No Result
View All Result
  • Home
  • World
    • Africa
    • Americas
    • Asia
    • Europe
    • Middle East
    • Oceania
  • Politics
  • Business
  • Technology
  • Health
  • Science
  • Sports
  • Entertainment
  • Culture
No Result
View All Result
Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports
No Result
View All Result
Home Health

WHO Launches Clinical Trial of Two Ebola Treatments as Congo’s Bundibugyo Outbreak Grows

Study will assess whether two antiviral therapies can improve survival during the ongoing Ebola outbreak.

The Daily Desk by The Daily Desk
July 3, 2026
in Health, Medical Research & Medicine
0
Healthcare workers at an Ebola treatment center during Congo clinical trial - AP Photo/Moses Sawasawa, File

Researchers begin testing two experimental Ebola treatments during Congo outbreak. - AP Photo/Moses Sawasawa, File

The World Health Organization (WHO) has launched a clinical trial in the Democratic Republic of Congo to evaluate two potential treatments for Ebola as the country continues to battle a growing outbreak caused by the less common Bundibugyo strain of the virus.

WHO Director-General Tedros Adhanom Ghebreyesus announced Thursday that the first participant has been enrolled in the study, marking the start of a closely watched effort to identify therapies that could improve patient survival.

The Bundibugyo virus is one of several viruses capable of causing Ebola disease, but unlike some other Ebola strains, it currently has no approved vaccine or treatment specifically designed for it. According to WHO, more than 1,400 people have been diagnosed during the outbreak, while 438 have died. More than 200 patients have recovered after receiving supportive medical care, particularly when treatment began early.

Tedros said the trial represents an important opportunity to generate evidence while responding to the outbreak.

“The trial offers real hope that we can deliver concrete results for – and with – the communities at the heart of the outbreak,” he said in a statement.

Two Treatments Under Evaluation

Researchers will investigate whether either of two therapies can improve survival among Ebola patients.

One treatment is remdesivir, an antiviral drug developed by Gilead Sciences that is approved for treating COVID-19. Laboratory studies have suggested it may have activity against the Bundibugyo virus, although its effectiveness against this outbreak remains unproven.

The second treatment is MBP134, an experimental antibody therapy developed by Mapp Biopharmaceutical. The engineered antibodies are designed to target multiple Ebola viruses, including the Bundibugyo strain.

Under the study design, every participant will receive the current standard supportive care. Patients will then be randomly assigned to receive remdesivir, MBP134, both treatments together, or supportive care alone.

■ Related News

Map shows a reported boat collision near Ngombe-Lukolela on the Congo River in Équateur province, Democratic Republic of Congo.

Congo River Boat Collision Kills at Least 30, Dozens Missing

October 6, 2026
Nobel Prize medal for medicine awarded in 1945 to Alexander Fleming, displayed at the National Museum of Scotland in Edinburgh.

Nobel Prize Week Opens in Stockholm With 2026 Medicine Award

October 5, 2026
U.S. military personnel train volunteers for Ebola treatment units at the National Police Training Center in Paynesville, Liberia.

Congo Ebola Outbreak Surpasses 4,000 Deaths as Treatment Center Burns

October 3, 2026
Health workers prepare to bury an infant during an Ebola outbreak in Bembi, Democratic Republic of the Congo, on September 1, 2026.

WHO Warns Congo Is Running Short of Health Workers as Ebola Spreads

September 24, 2026

Dr. Vasee Moorthy, a WHO research adviser, said researchers will monitor survival for 28 days after treatment begins.

Trial Could Take Months

Health officials cautioned that determining whether either therapy is effective will require time.

Moorthy said the study could take several months and may require as many as 1,000 participants before researchers can determine whether one or both treatments improve outcomes. However, if either therapy demonstrates a particularly strong benefit, meaningful results could emerge sooner with fewer participants.

The trial is currently operating at a single Ebola treatment center in Congo’s Ituri province.

Security Challenges Continue

Expanding the study may depend on improving security conditions in eastern Congo, where armed violence has repeatedly disrupted healthcare operations.

The affected region has experienced attacks involving healthcare workers responding to the outbreak, complicating efforts to diagnose patients, provide treatment, and contain transmission of the virus, which spreads through direct contact with the bodily fluids of infected individuals.

Officials said they intend to extend the study to additional treatment centers once conditions allow.

International Collaboration Supports Research

WHO said sufficient supplies of both treatments have been donated for the trial. Gilead Sciences provided remdesivir, while doses of MBP134 are owned by the U.S. government, which funded research into the experimental therapy.

If either treatment proves effective, researchers said the next challenge will be ensuring patients can continue receiving the therapy beyond the clinical trial.

The study is supported by WHO and conducted through a partnership involving Congo’s National Institute for Biomedical Research (INRB), the University of Oxford, the Institute of Tropical Medicine in Antwerp, and other international health organizations.

Tags: Ebola, Bundibugyo Virus, Democratic Republic of Congo, World Health Organization, Clinical Trial, Remdesivir, MBP134, Infectious Diseases, Public Health, Ebola Treatment, Ituri Province, Medical Research

Tags: #Africa#Bundibugyo#Ebola#EbolaOutbreak#GlobalHealth#HealthcareResearch#InfectiousDiseases#MBP134#MedicalResearch#Remdesivir
The Daily Desk

The Daily Desk

The Daily Desk is the editorial byline of Journos News, representing reporting produced by the newsroom across world news, politics, business, technology, disasters, and other areas of public interest. Stories published under this byline are independently researched, verified, and edited in accordance with Journos News’ editorial standards, with an emphasis on accuracy, transparent sourcing, attribution, context, and editorial independence.

Related Posts

Laboratory scientist performs real-time PCR testing in Ghana during efforts to investigate the mpox outbreak in West Africa in November 2022.

West Africa’s Outbreak Warning: Can Its Health Systems Detect the Next Epidemic in Time?

by The Daily Desk
September 19, 2026
0

LOME, Togo - Nearly a decade after Ebola exposed some of West Africa’s most serious...

Ayo, the lion mascot of the Dakar 2026 Youth Olympic Games, representing Senegalese youth and the first Olympic event in Africa.

Olympic Flame Arrives in Senegal Ahead of Africa’s First Olympic Event

by The Daily Desk
September 14, 2026
0

DAKAR, Senegal - The Olympic flame for the Dakar 2026 Youth Olympic Games arrived in...

Ozempic semaglutide 0.5 mg packaging displayed in a pharmacy, photographed in August 2023.

New Study Links Semaglutide to Fewer Asthma Attacks in Real-World Analysis

by The Daily Desk
September 10, 2026
0

BARCELONA, Spain - People taking semaglutide had fewer asthma exacerbations in a large real-world analysis...

Scientific illustration showing osteoclast-mediated bone resorption and signaling pathways that support bone replacement by osteoblasts.

Scientists Find Molecular Switch That Could Strengthen Bones and Slow Bone Loss

by The Daily Desk
September 10, 2026
0

LEIPZIG, Germany — Scientists have identified a molecular receptor that appears to help regulate the...

Hotel employees participate in Ebola training in Conakry, Guinea, as part of public health preparedness activities.

Congo Ebola Outbreak Kills 317 in One Week as Health Crisis Accelerates

by The Daily Desk
August 26, 2026
0

BUNIA, Congo — An Ebola outbreak in eastern Congo killed 317 people in the seven...

MSF staff member helps a CDC doctor secure his face mask before entering an Ebola treatment unit in Liberia.

Congo says quarantined river boat passengers test negative for Ebola

by The Daily Desk
August 10, 2026
0

KINSHASA, Congo - No Ebola cases have been detected among more than 200 passengers quarantined...

Army medic checks patients' temperatures during Ebola treatment training at a simulated treatment center near York, England.

US citizen tests positive for Ebola as Congo outbreak continues to spread

by The Daily Desk
August 10, 2026
0

KINSHASA, Congo - A U.S. citizen working for a humanitarian organization in Congo has tested...

Personal protective equipment is arranged for medical staff during an Ebola response training exercise at an Army health clinic.

Congo Quarantines Nearly 200 River Passengers After Suspected Ebola Death Near Kinshasa

by The Daily Desk
August 7, 2026
0

BUNIA, Congo - Congolese health authorities have placed nearly 200 passengers from a riverboat under...

A nurse wearing protective gloves administers a vaccine injection into an adult patient's upper arm during an immunization appointment.

Experimental Vaccines Show Early Promise in Preventing Colon Cancer for People With Lynch Syndrome

by The Daily Desk
August 6, 2026
0

Researchers are testing a new generation of experimental vaccines designed to prevent colorectal cancer in...

Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, attends the European Union–African High-Level Event on Health in Brussels, Belgium.

DR Congos Bundibugyo Ebola Outbreak Becomes Countries Largest as Cases Surge Across Five Provinces

by The Daily Desk
August 6, 2026
0

The Democratic Republic of the Congo's outbreak of Ebola disease caused by the Bundibugyo virus...

Load More
Next Post
Iranian officials attend funeral preparations for Ayatollah Ali Khamenei in Tehran. - Office of the Iranian Supreme Leader via AP

Iranian General Reappears as Tehran Prepares Multi-Day Funeral for Ayatollah Ali Khamenei

Traders monitor Wall Street as technology stocks lead market declines. - AP Photo/Richard Drew

Wall Street Ends Lower as AI Stocks Slide Despite Broad Market Gains

RECOMMENDED

U.S. Special Envoy Steve Witkoff and Jared Kushner meet Russian President Vladimir Putin in the Red Drawing Room at the Kremlin in Moscow on September 5, 2026.

US Envoys Meet Putin and Zelenskyy as Ukraine Peace Talks Resume

November 13, 2026
Journos News logo centered over a white world map on a gray background, with the website address JOURNOSNEWS.COM beneath the logo.

South Korea Bus Crash Injures 70 After Colliding With 31 Vehicles

November 13, 2026
NVIDIA founder and CEO Jensen Huang during a fireside chat in Stanford University's CS 153 course on April 30, 2026.

Jensen Huang’s Scandal Tests His Status as a Taiwan Technology Icon

November 13, 2026
Map showing the location of Nasser Medical Complex in Khan Younis, southern Gaza Strip, near the Egyptian border and Mediterranean Sea. - Journos News, File

Israeli Strike on Gaza’s Nasser Hospital Kills Six, Including Doctor and Child

November 13, 2026
Journos News logo centered over a white world map on a gray background, with the website address JOURNOSNEWS.COM beneath the logo.

Washington DC Gym Shooting Leaves One Dead and Four Injured; Suspect Dies

November 13, 2026

MOST VIEWED

  • Official portrait of Indonesian Vice-President Gibran Rakabuming, taken in 2024.

    Indonesia’s Vice-President Gibran Resigns Amid Dispute Over Education Credentials

    0 shares
    Share 0 Tweet 0
  • South Korea Bus Crash Injures 70 After Colliding With 31 Vehicles

    0 shares
    Share 0 Tweet 0
  • Jensen Huang’s Scandal Tests His Status as a Taiwan Technology Icon

    0 shares
    Share 0 Tweet 0
  • Washington DC Gym Shooting Leaves One Dead and Four Injured; Suspect Dies

    0 shares
    Share 0 Tweet 0
  • Hunt for Clues in Deadly Brooklyn Building Collapse Will Take Time

    0 shares
    Share 0 Tweet 0
JournosNews logo

Journos News delivers globally neutral, fact-based journalism that meets international media standards — clear, credible, and made for a connected world.

  • Categories
  • World News
  • Politics
  • Business & Markets
  • Technology
  • Health
  • Science
  • Sports
  • Arts & Culture
  • Resources
  • Editorial Standards
  • Submit a Story
  • Advertise with Us
  • Syndication & Partnerships
  • Site Map
  • Press & Media Kit
  • Editorial Team
  • Careers

Join thousands of readers receiving the latest updates, tips, and exclusive insights straight to their inbox. Never miss an important story again.

  • About Us
  • Editorial & Trust Center
  • Contact Us
  • Privacy Policy
  • Terms of Use & Copyright Notice

© JournosNews.com All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
JournosNews

Independent Journalism.
Verified Facts.

You're about to read a professionally edited article from JournosNews.com.

Every article is produced in accordance with our editorial standards, emphasizing factual accuracy, transparent attribution, fairness, editorial independence, and meaningful context.

Editorial Standards
No Result
View All Result
  • Home
  • World
    • Africa
    • Americas
    • Asia
    • Europe
    • Middle East
    • Oceania
  • Politics
  • Business
  • Technology
  • Health
  • Science
  • Sports
  • Entertainment
  • Culture

© JournosNews.com All rights reserved.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.